Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL-1 CAR-T in Children With Relapsed/Refractory Acute Myeloid Leukemia
NCT07338357Phase 1Withdrawn
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of CB-012 in acute myeloid leukemia (AML), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Incidence of Treatment-Related Adverse Events up to 2 years. Planned start Jan 2026; status: withdrawn.
02
Drugs
CB-012
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07338357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07338357.